Enliven Therapeutics (ELVN) Cash from Investing Activities Growth (1y) (2020 - 2026)
Enliven Therapeutics (ELVN) Cash from Investing Activities Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Enliven Therapeutics | 3.33 Bn | 2.88 Bn | - | 2,880.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,880.10% |
| Dec 31, 2025 | 1,602.75% |
| Sep 30, 2025 | -127.37% |
| Jun 30, 2025 | -445.34% |
| Mar 31, 2025 | 107.98% |
| Dec 31, 2024 | -98.12% |
| Sep 30, 2024 | 141.71% |
| Jun 30, 2024 | 77.78% |
| Mar 31, 2024 | -57,593.55% |
| Dec 31, 2023 | 38,402.97% |
| Sep 30, 2023 | -253,821.43% |
| Jun 30, 2023 | -49,905.94% |
| Mar 31, 2023 | 84.02% |
| Dec 31, 2022 | 99.30% |
| Sep 30, 2022 | 99.84% |
| Jun 30, 2022 | -108.94% |
| Mar 31, 2022 | -101.06% |
| Dec 31, 2021 | -168.32% |
| Sep 30, 2021 | 14.10% |
| Jun 30, 2021 | 110.45% |